靶点- |
作用机制Anion transport proteins 调节剂 [+1] |
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2017-10-24 |
A randomized, double-blind, placebo-controlled investigation of the safety, tolerability and pharmacokinetics of 1% SPL7013 nasal spray in healthy volunteers when administered four times a day for 14 days
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours. - SN38-SPL9111 in advanced solid tumours
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours
100 项与 Starpharma Pty Ltd. 相关的临床结果
0 项与 Starpharma Pty Ltd. 相关的专利(医药)
100 项与 Starpharma Pty Ltd. 相关的药物交易
100 项与 Starpharma Pty Ltd. 相关的转化医学